top of page

Janssen submits application to the EMA to expand use of DARZALEX® (daratumumab)

Janssen-Cilag International NV today announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX®▼ (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy.


Click on this link for more information.

source: http://www.europeanpharmaceuticalreview.com/43458/news/industry-news/janssen-application-ema-expand-darzalex-daratumumab/


#Pharmanews

Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page